Pancreatic Cancer Research

ResearcherNational Cheng Kung University HospitalActive in the last 2 years

Yan‐Shen Shan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2457-5189; OpenAlex author ID A5028067779, A5112030942. Sources: ClinicalTrials.gov.

Their work

Papers
73 (first author 3, last author 21)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
122
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 1 paper · 2016: 4 papers · 2017: none · 2018: 3 papers · 2019: 6 papers · 2020: 7 papers · 2021: 3 papers · 2022: 14 papers · 2023: 8 papers · 2024: 5 papers · 2025: 8 papers, 1 trial · 2026: 10 papers

Papers 50 of 73

  1. Machine Learning-Based Classification of Depression Using Inflammatory Biomarkers in Pancreatic Cancer Patients. Co-author DOI 10.1002/kjm2.70094↗
  2. Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors. Last author DOI 10.1007/s13304-026-02686-8↗
  3. TBC1D23 drives lymphatic metastasis in pancreatic ductal adenocarcinoma by altering EGFR cell surface dynamics and signaling. Last author DOI 10.1007/s13402-026-01203-8↗
  4. Heparanase blockade sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy and unleashes antitumor immunity. Last author DOI 10.1016/j.biopha.2026.119442↗
  5. SLOG versus modified FOLFIRINOX as first-line treatment for advanced pancreatic cancer: A randomized phase II trial (TCOG T5217). Co-author DOI 10.1016/j.ejca.2026.116229↗
  6. Improved survival with adding-on strategy after failure of nanoliposomal irinotecan plus 5-fluorouracil and leucovorin in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jfma.2025.02.035↗
  7. Enhanced quality of life and survival time in pancreatic cancer patients with first-line chemotherapy: A prospective observational study in Taiwanese populatio… First author DOI 10.1016/j.jfma.2026.07.023↗
  8. A decade of progress: a before and after study on improved survival in pancreatic cancer through evolving multimodal therapy. Last author DOI 10.1097/js9.0000000000005024↗
  9. Prognostic Value of Cognitive Impairment in Patients With Pancreatic Cancer. Co-author DOI 10.1097/psy.0000000000001465↗
  10. A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC. Co-author DOI 10.1158/1078-0432.ccr-25-4564↗
  11. Risk Factors and Vascular Features Associated With Local Recurrence in Pancreatic Cancer Post-Pancreaticoduodenectomy: A Retrospective Cohort Study. Last author DOI 10.1002/cnr2.70267↗
  12. Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition. Co-author DOI 10.1002/ctm2.70394↗
  13. Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study in T… Last author DOI 10.1007/s00432-025-06353-0↗
  14. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  15. Macrophage activation determines muscle wasting in pancreatic cancer. Last author DOI 10.1038/s41388-025-03434-9↗
  16. Melanophilin-induced primary cilia promote pancreatic cancer metastasis. Co-author DOI 10.1038/s41419-025-07344-2↗
  17. Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells. Co-author DOI 10.1186/s12943-024-02207-4↗
  18. Radiocleavable rare-earth nanoactivators targeting over-expressed folate receptors induce mitochondrial dysfunction and remodel immune suppressive microenviron… Co-author DOI 10.1186/s12951-025-03657-8↗
  19. Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis. Co-author DOI 10.1002/advs.202306373↗
  20. Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00262-024-03821-3↗
  21. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.03.014↗
  22. Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment. Last author DOI 10.1158/1535-7163.mct-23-0767↗
  23. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan. Co-author DOI 10.1186/s12929-024-01008-7↗
  24. Carbohydrate Antigen 19-9 Response to Initial Adjuvant Chemotherapy Predicts Survival and Failure Pattern of Resected Pancreatic Adenocarcinoma but Not Which P… Co-author DOI 10.1016/j.ijrobp.2023.02.061↗
  25. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  26. Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer. Co-author DOI 10.1038/s41467-023-42402-3↗
  27. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study. Last author DOI 10.1097/js9.0000000000000495↗
  28. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  29. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers15041008↗
  30. New insights into the role of adipocytes in pancreatic cancer progression: paving the way towards novel therapeutic targets. Last author DOI 10.7150/thno.82911↗
  31. Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination. Co-author PMID 37693128↗
  32. Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovo… Co-author DOI 10.1002/jhbp.1128↗
  33. A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma - T… Co-author DOI 10.1016/j.ejca.2022.06.043↗
  34. Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer. Last author DOI 10.1016/j.molmet.2022.101576↗
  35. RNA bisulfite sequencing reveals NSUN2-mediated suppression of epithelial differentiation in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02325-7↗
  36. A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative On… Co-author DOI 10.1038/s41416-021-01649-7↗
  37. Cancer-cell-derived cell-free DNA can predict distant metastasis earlier in pancreatic cancer: a prospective cohort study. Last author DOI 10.1177/17588359221106558↗
  38. Review of the endocrine organ-like tumor hypothesis of cancer cachexia in pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.1057930↗
  39. Dosing Pattern and Early Cumulative Dose of Liposomal Irinotecan in Metastatic Pancreatic Cancer: A Real-World Multicenter Study. Co-author DOI 10.3389/fonc.2022.800842↗
  40. The Differential Clinical Impacts of Cachexia and Sarcopenia on the Prognosis of Advanced Pancreatic Cancer. Last author DOI 10.3390/cancers14133137↗
  41. Semaphorin 6C Suppresses Proliferation of Pancreatic Cancer Cells via Inhibition of the AKT/GSK3/β-Catenin/Cyclin D1 Pathway. Co-author DOI 10.3390/ijms23052608↗
  42. The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan. Last author PMID 35530292↗
  43. Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: a single institution experience. Co-author PMID 35693078↗
  44. Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma rec… Co-author PMID 36225629↗
  45. The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic duc… First author PMID 36504882↗
  46. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: Fr… First author DOI 10.1016/j.radonc.2021.02.037↗
  47. No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol. Co-author DOI 10.1038/s41598-021-94111-w↗
  48. Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study. Co-author DOI 10.1177/17588359211058255↗
  49. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Co-author DOI 10.1016/j.ejca.2019.10.023↗
  50. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort. Co-author DOI 10.1038/s41598-020-64421-6↗

Trials 1

  1. Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomize… Principal investigator NCT06816914↗

Closest collaborators

The 25 strongest of 122 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li‐Tzong Chen · 35 shared papers, 2011–2026 · strength 4.77
  2. Nai‐Jung Chiang · 23 shared papers, 2016–2026 · strength 3.38
  3. Yung‐Yeh Su · 20 shared papers, 2020–2026 · strength 3.33
  4. Ya‐Chin Hou · 20 shared papers, 2014–2026 · strength 3.32
  5. Ying‐Jui Chao · 14 shared papers, 2014–2026 · strength 2.18
  6. Chung‐Pin Li · 14 shared papers, 2020–2026 · strength 2.01
  7. Jen‐Shi Chen · 15 shared papers, 2011–2026 · strength 1.98
  8. Hao‐Chen Wang · 11 shared papers, 2014–2026 · strength 1.80
  9. Ping‐Jui Su · 7 shared papers, 2022–2026 · strength 1.77
  10. Li‐Yuan Bai · 11 shared papers, 2021–2026 · strength 1.63
  11. Ting‐Kai Liao · 6 shared papers, 2022–2026 · strength 1.53
  12. Tai‐Jan Chiu · 11 shared papers, 2015–2026 · strength 1.46
  13. Shih‐Hung Yang · 10 shared papers, 2021–2024 · strength 1.42
  14. Wen‐Chi Chou · 10 shared papers, 2021–2025 · strength 1.37
  15. Yen‐Yang Chen · 9 shared papers, 2021–2024 · strength 1.20
  16. Wen‐Chun Hung · 8 shared papers, 2016–2025 · strength 1.16
  17. Cheng‐Feng Lin · 3 shared papers, 2026 · strength 1.14
  18. Po See Chen · 3 shared papers, 2026 · strength 1.14
  19. Chien‐Jui Huang · 6 shared papers, 2022–2026 · strength 1.12
  20. Cheng‐Ming Peng · 8 shared papers, 2021–2024 · strength 1.06
  21. Hui‐Jen Tsai · 7 shared papers, 2018–2026 · strength 1.01
  22. Amornthep Jankaew · 2 shared papers, 2026 · strength 0.79
  23. Siao Muk Cheng · 3 shared papers, 2024–2026 · strength 0.63
  24. Chang-Jung Chen · 2 shared papers, 2024–2026 · strength 0.57
  25. Shaw‐Jenq Tsai · 3 shared papers, 2020–2025 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.